Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06623890 · ClinicalTrials.gov registry record
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
A clinical trial of Friedreich Ataxia, sponsored by Biogen.
- Recruiting
- Registry status
- 300
- Enrollment target
- 14
- Study locations
NCT06623890: Recruiting study of Friedreich Ataxia, sponsored by Biogen.
NCT06623890 is a study of Friedreich Ataxia that is actively recruiting participants, run by Biogen. The registered enrollment target is 300 participants, below the 428-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (30% lower). The trial reports 14 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06623890, a study of Friedreich Ataxia, is actively recruiting participants, sponsored by Biogen.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 14
- Study locations
Study Summary
In this study, researchers will learn more about the safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This is a drug available for doctors to prescribe for people with Friedreich's Ataxia, also known as FA. This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will be found using a group called the Friedreich's Ataxia Global Clinical Consortium (FA GCC) UNIFIED Natural History Study (UNIFAI). The FA-GCC is a group of study research centers that helps provide clinical care for FA patients and also helps researchers learn more about how FA affects patients over a long time. The main objective of this study is to collect safety information in participants with FA from UNIFAI. Some of the participants in this study will be prescribed BIIB141 for the first time by their own doctors. Some of the participants will have started taking BIIB141 after joining UNIFAI, but less than 12 months before joining this study. The main questions researchers want to answer in this study are: * How many participants had serious adverse events (SAEs)? An adverse event is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care. * How many participants had adverse events (AEs) related to heart failure or liver damage caused by the drug? Researchers will also learn more about : • Why and when participants stopped treatment, left the study, or took more of the drug than was prescribed This study will be done as follows: * Participants will be screened to check if they can join the study. * After joining the study, the participants who had never started BIIB141 treatment before must start it within 6 months. Otherwise, all participants will take BIIB141 throughout this study as prescribed by their own doctor. * During the study, each participant's doctor will decide how often the participant visits the s
Conditions Studied
Interventions
- DRUG Omaveloxolone
Study Locations (14)
Other
- Medizinische Universität Innsbruck - Innsbruck
- HUB-Hôpital Erasme - Brussels
- University Hospital Aachen - Aachen
- Klinikum der Universität München - Munich
- Scientific Institute, IRCCS E. Medea - Conegliano
- Fondazione I.R.C.C.S. Istituto Neurologico C. Besta - Milan
- Ospedale Pediatrico Bambino Gesu - Rome
- Stichting Radboud universitair medisch centrum - Nijmegen
California
- UCLA Neurology - Los Angeles
Colorado
- University of Colorado - Aurora
Florida
- University of Florida - Gainesville
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Prague
- Center for hereditary ataxias, Motol - Motol
Baden-Würtemberg
- Universitätsklinikum Tübingen - Tübingen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2029-10-01 |
What NCT06623890 shows while recruiting
NCT06623890 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 428-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Friedreich Ataxia appearing as the primary indexed condition, and to 1 intervention - of which Omaveloxolone is the first listed.
NCT06623890 lists 14 locations in 7 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06623890 about?
NCT06623890 is a clinical study titled "A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors". In this study, researchers will learn more about the safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This is a drug available for doctors to prescribe for people with Friedreich's Ataxia, also known as FA. This is known as an "observational" study, which collects health information abo...
What is the current status of trial NCT06623890?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-12-12. Estimated completion is 2029-10-01.
What conditions does trial NCT06623890 study?
This clinical trial studies the following conditions: Friedreich Ataxia.
What interventions are being tested in trial NCT06623890?
The interventions under investigation include: Omaveloxolone (DRUG).
Who is sponsoring clinical trial NCT06623890?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06623890 being conducted?
This trial has 14 study locations across California, Colorado, Florida, Pennsylvania, Prague. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Friedreich Ataxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06623890's enrollment target sits among peer trials
300 3rd of 14 higher than 11 of 14 other Friedreich Ataxia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Friedreich Ataxia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Course Of Disease In Participants With FA-CM
RECRUITING
-
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
RECRUITING · Phase 1
-
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
RECRUITING · Phase 1
-
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
RECRUITING
-
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)
RECRUITING · Phase 3
-
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI